CION Ameerpet
Immunotherapy · When It Stops Working & Difficult Decisions
Continuing Immunotherapy After the Scan Got Worse — When It Makes Sense
Being told the scan is worse and that the same treatment should continue sounds like a contradiction. It is not always one. Immunotherapy can produce delayed responses, and in a patient who remains well a short, defined period of continued treatment with a confirmation scan is a recognised way to find out which is happening.
Medically reviewed by Dr. Bharati Devi Gorantla, Medical Oncologist, MBBS · MD · DM (Adyar, Chennai) · ECMO · MRCP SCE (UK) · Last reviewed August 2026
- One scan is not always the answer — Immune responses can be delayed, and inflammation can make a tumour measure larger before it shrinks.
- Confirmed and unconfirmed are different — Ask which yours is — immune-specific criteria separate the two and set a repeat scan.
- It suits patients who are clinically well — Deterioration, an organ at risk or a clearly better option all point the other way.
- Agree the stop rule at the same time — The most useful question in the room is: what would make us stop, and by when?
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
The short answer
Why Would Anyone Continue Immunotherapy After the Cancer Has Grown?
Because a single scan showing growth does not always mean the treatment has failed. Immunotherapy can produce delayed responses, and inflammation can make a tumour measure larger before it shrinks. In a patient who remains clinically well, continuing under a defined review plan is a recognised strategy for finding out which is happening.
Immunotherapy does not behave on a scan the way chemotherapy does. The response can be delayed, and immune cells moving into a tumour can make it measure larger before it gets smaller. That is why a separate framework, iRECIST, was developed for assessing response to these drugs, and why unconfirmed growth is treated differently from confirmed growth.
The strategy is built around confirmation, not around hope. Under iRECIST, growth that has not yet been confirmed can be followed by a repeat scan after a short interval, commonly four to eight weeks, while treatment continues in a patient who is clinically stable. The point of continuing is to find out, not to avoid the conversation.
It is not the same as refusing to change course. Continuing beyond progression is a defined, time-limited plan with a review date. If it turns into treatment that carries on because nobody set a point to stop, something has gone wrong with the plan rather than with the drug.
How you are is the deciding input. A patient who feels well, is eating, is not losing weight and has no new symptoms is in a very different position from one who is deteriorating. Continuing is considered for the first group and generally not for the second.
The honest version
What Is Pseudoprogression, and How Often Does It Happen?
Pseudoprogression is when a tumour appears larger on a scan because immune cells have moved into it, not because the cancer has grown. It is uncommon. In most patients, growth on a scan is real growth. That is precisely why the strategy is built around a confirmation scan rather than around assuming the best.
Do not plan around it. It is worth knowing about because it is the reason confirmation scans exist, but it is not common enough to be a reasonable expectation. If you are hoping that the growth on your scan will turn out to be pseudoprogression, the more useful frame is that a confirmation scan will tell you either way within a few weeks.
It is also not the only reason to continue. Some patients have a mixed picture in which most of the disease stays controlled and one area grows. Some remain clinically well with modest radiological change. Those are separate arguments for continuing under review, and they do not depend on pseudoprogression at all.
Symptoms are the tiebreaker. Growth on a scan in a person who feels well is a different situation from growth in a person who has become breathless, has new pain or is losing weight. Clinical deterioration alongside radiological growth is usually taken as confirmation, and the plan changes.
Did you know?
Response to immunotherapy is assessed with its own framework, iRECIST, rather than the criteria used for chemotherapy. It separates unconfirmed progression from confirmed progression, and allows treatment to continue in a patient who is clinically stable while a repeat scan, commonly four to eight weeks later, settles the question. Asking whether your progression is confirmed or unconfirmed is a fair and specific question to put to your oncologist.
Two different situations
Who Is Treatment Beyond Progression Actually Considered For?
Mainly patients who remain clinically stable and well. NCCN and ESMO both describe continuing beyond radiological progression as something that may be considered in selected patients rather than a routine approach. It is generally not considered for someone who is deteriorating, who has a site threatening an organ, or who has a clearly better option available.
This table is a general contrast to help you follow the conversation. It is not a rule that decides your case.
| Question | Continuing is more often considered | Continuing is generally not considered |
|---|---|---|
| How you are clinically | Feeling well, eating, weight steady, activity unchanged | Deteriorating, losing weight, new or worsening symptoms |
| What the scan shows | Limited or borderline growth, or one area growing while the rest holds | Clear growth across several sites, or a rapid change since the last scan |
| Whether the growth is confirmed | Not yet confirmed, with a repeat scan due | Already confirmed on a repeat scan |
| Whether a site is causing danger | No site is threatening an organ, an airway or the spinal cord | A deposit is causing or about to cause an urgent problem |
| What the alternative is | No clearly better option is immediately available | A recognised next-line treatment is available and appropriate |
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Asked to Continue Immunotherapy Despite a Worse Scan?
It can be a sound plan or a drift, and the difference is whether a confirmation scan and a stop rule were agreed. A medical oncologist can review both with you before the next cycle.
Step by step
How Is the Decision Actually Made?
In five moves: your clinical condition is assessed first, the new images are compared directly against the earlier ones, an interval for the confirmation scan is agreed, a stop rule is written down at the same time, and the cost and insurance position is settled before the next cycle rather than after it.
1
The clinical assessment comes before the scan is discussed
How you are is the first input, not the second. Weight, appetite, breathlessness, pain, how far you can walk and whether any of that has changed in the last month. A patient who is deteriorating clinically is not usually a candidate for continuing, whatever the images show.
2
The images are compared directly against the earlier ones
Not against the previous report, against the previous pictures. Ask that your baseline and interim images travel with the new ones. Response-assessment imaging is coordinated at partner imaging centres, so this needs to be requested rather than assumed.
3
An interval for the confirmation scan is agreed and written down
Under the iRECIST framework, growth that is not yet confirmed is followed by a repeat scan after a short interval, commonly four to eight weeks, to establish whether the progression is real. Ask for the date rather than leaving it open.
4
A stop rule is agreed at the same time as the plan to continue
The single most useful sentence in this conversation is: what would make us stop? New symptoms, a specific amount of further growth, a drop in how you are functioning. Agreeing it now prevents the drift where treatment continues because nobody named a point to review it.
5
The cost and cover conversation happens before the next cycle, not after it
Ask for a written estimate for each further cycle, and ask your insurer or scheme in writing whether cover continues once progression is recorded in your file. Finding this out afterwards is the expensive way to find it out.
Ask it out loud
The Cost Question Nobody Raises First
Ask for a written estimate for each further cycle. Not a verbal figure at the counter and not a total for an unspecified number of cycles. A written estimate per cycle lets a family work out how many they can actually sustain, which is a legitimate input into the decision rather than an embarrassing one.
Ask your insurer or scheme, in writing, before the next cycle. Some policies and scheme approvals are framed around documented disease status, and progression recorded in your file can change how a claim is assessed. Get the answer in writing beforehand. Discovering it after two more cycles have been given is how families end up with bills they did not expect. Any cost figure you are quoted anywhere should be treated as indicative only.
Ask what happens to the other options while you continue. If four to eight weeks of continued treatment would take a next-line option off the table, that changes the arithmetic. Often it does not, but it should be asked rather than assumed.
Say the cost constraint out loud in clinic. Oncologists cannot factor in a limit they have not been told about, and a family that stops treatment silently because it has run out of money is worse off than one that plans around what it has. This is one of the most common unspoken factors in cancer decisions in India, and naming it changes the plan for the better far more often than it causes offence.
A decision, not a default
What If Continuing Is Not the Right Answer for You?
Declining to continue is a considered medical decision. Some people, having heard that continuing means more visits, more cost and a scan in six weeks that may say the same thing, decide that the trade is not worth it for them. That is a legitimate choice and it should be recorded as one, not treated as giving up.
Palliative care belongs in this conversation from the beginning rather than at the end of it. It is symptom and quality-of-life support that runs alongside cancer treatment, and ASCO and WHO both describe it as a service to introduce early. You can continue immunotherapy under review and see a palliative care team in the same week; the two are not alternatives.
The question worth putting to your oncologist, plainly, is what the goal of continuing would be. Disease control, symptom relief, or time for something specific? An answer to that makes the decision far easier than any amount of discussion about the scan itself.
A defined plan, not an open-ended one
Continue With a Review Date, or Change With a Reason
Either decision is reasonable. What is not reasonable is treatment continuing because nobody named the point at which it would be reconsidered.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Treatment Beyond Progression — Your Questions Answered
Why would a doctor continue immunotherapy after the cancer has grown?
Because a single scan showing growth does not always mean the treatment has failed. Immunotherapy can produce delayed responses, and immune cells moving into a tumour can make it measure larger before it becomes smaller. Response to these drugs is therefore assessed with an immune-specific framework, iRECIST, which separates unconfirmed progression from confirmed progression and allows treatment to continue in a clinically stable patient while a repeat scan settles the question. The point of continuing is to find out, within a defined period, rather than to avoid changing course. It should always come with a review date.
What is pseudoprogression?
It is when a tumour appears larger on a scan because immune cells have moved into it, rather than because the cancer itself has grown. It is uncommon, and in most patients growth on a scan is real growth, so it is not something to plan around or to hope for. It matters mainly because it is the reason confirmation scans exist. If your oncologist suggests repeating imaging after a short interval before changing treatment, this is usually part of the reasoning. Symptoms are the tiebreaker: growth on a scan in someone who feels well is a different situation from growth in someone who has become breathless or is losing weight.
Who is treatment beyond progression suitable for?
Mainly patients who remain clinically stable and well. NCCN and ESMO both describe it as something that may be considered in selected patients rather than as a routine approach. The factors that point towards it are feeling well, a steady weight, unchanged activity, limited or borderline growth on the scan, progression that is not yet confirmed, and no clearly better alternative immediately available. The factors that point away from it are clinical deterioration, rapid change since the last scan, growth across several sites, a deposit threatening an organ or the spinal cord, or an appropriate next-line treatment being available.
How long is immunotherapy continued after progression before deciding?
Usually until a confirmation scan, rather than indefinitely. Under the iRECIST framework the repeat scan is commonly done four to eight weeks after the first sign of growth, which is deliberately shorter than a routine assessment interval. Ask for the date of that scan to be fixed at the same time as the decision to continue, and ask what would make the plan change sooner, such as new symptoms or a fall in how well you are functioning. A plan to continue without a named review point is not really a plan, and that is the situation worth pushing back on.
Will insurance keep paying for immunotherapy after progression is recorded?
Ask your insurer or scheme in writing, before the next cycle. Some policies and scheme approvals are framed around documented disease status, so progression recorded in your file can change how a claim is assessed. This varies between insurers and between policies, so a general answer is not worth much. What is worth a great deal is getting your own answer in writing beforehand rather than after two more cycles have been given. Ask the hospital for a written estimate per cycle at the same time, and treat any figure you are quoted as indicative only.
Is continuing treatment beyond progression the same as giving up on other options?
No, and it is worth asking that question directly. In most situations a defined period of continued treatment with a confirmation scan does not remove a later option, but whether that holds in your case depends on your cancer type, what has already been used and how well you are. Ask your oncologist plainly whether four to eight weeks of continuing would take anything off the table. Ask too what the goal of continuing would be: disease control, symptom relief, or time for something specific. Declining to continue is equally a considered decision, and palliative care can run alongside either choice.
This page is general patient-education information, not a substitute for the written guidance your own oncology team gives you based on your specific diagnosis, scans and treatment history.